ASMB

Assembly Biosciences

ASMB

Attention (50-day avg)0%

Attention rank (50-day avg)#2,572

Bullish sentiment (50-day avg)95%

Price to earnings ratio19.1

Market capitalization480.7M

Earnings per share1.24

Dividend yield (TTM)—

Revenue (annual)72.3M

Net income (annual)-6.1M

Social

What share of all stock conversation is about ASMB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Jul 17

The stock price of ASMB is expected to increase to 3.00+ with high confidence.
A trade idea involves buying the $ASMB 30 Call for August 21 at 2.00.
ASMB is looking strong and is expected to continue increasing in value.

Generated by AI

Sentiment

Of the messages about ASMB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% +7.14	96.47% +9.44
Bearish	—	0% 0	0% -7.14	3.53% -9.44

Bullish· Jan 30

Assembly Biosciences, Inc. ($ASMB) has broken out and is gapping up, with some investors expecting a takeover by Gilead in the near future.
Closing above $1.16 per share would put $ASMB above the price Gilead paid to invest and collaborate with the company.
A strong close above $1.00 per share could meet the stock price requirements for a listing on the Nasdaq exchange.

Bearish· Oct 18

The market makers are allegedly shaking out weak hands in $ASMB, indicating a potential stop loss raid.
The significant short interest in $ASMB, with nearly 22M shares shorted yesterday, may be contributing to the current price drop.
The company's poor track record of cash utilization and preclinical/early-stage partnership deals, such as the Gilead partnership, may be causing investors to lose confidence in $ASMB.

Generated by AI

Topics

Of the messages about ASMB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	60%	79.86%
Earnings	0%	0%	0%	0.35%
Analysts	0%	0%	40%	14.84%
Controversies	0%	0%	0%	0.71%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	4.24%

Earnings· Feb 27

Assembly Biosciences, Inc. ($ASMB) is expected to announce earnings of -$0.79 per share.
The expected earnings announcement is related to the company's financial performance.
The earnings announcement is expected to provide insight into the company's financial health.

Announcements· Aug 8

Assembly Biosciences, Inc. (ASMB) announced positive interim results from its Phase 1b clinical study of ABI-5366, showing reductions in viral shedding rate and genital lesion rate in recurrent genital herpes.
ASMB has entered into a private placement with Gilead Sciences (GILD), where Gilead will purchase 2.3 million shares of ASMB common stock and accompanying Class A warrants and Class B at a price of $19.60 per share.
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings, with the company planning to use the funds to support the development of its chronic viral disease treatments, including ABI-5366.

Technical Analysis· Oct 17

The stock has shown a strong bullish engulfing pattern on the quarterly chart, indicating a potential continuation of the rally.
The Relative Strength Index (RSI) has exited the oversold zone, indicating a shift in the trend to a more bullish direction.
The stock has formed an inverted head and shoulders pattern, which is a bullish reversal pattern, and has also shown a breakout from the 18 level, indicating a potential continuation of the uptrend.

Generated by AI

Community

Of the messages about ASMB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	33.33%	63.64%	56.73%
Newcomers	100%	66.67%	36.36%	43.27%

Regulars· Feb 12

The open short interest for Assembly Biosciences Inc ($ASMB) has decreased to a micro float of 5.8 million outstanding shares.
The company's stock price is down, and its float is considered a micro float.
A catalyst or any momentum will be necessary to send the stock price higher.

Newcomers· Jul 17

Newcomers are bullish on $ASMB, expecting it to reach 3.00+.
Many are focusing on the $ASMB 30 Call for August 21 with prices ranging from 1.80 to 2.00.
Some are tracking their transactions and transactions history with $ASMB.

Generated by AI

News

New Strong Buy Stocks for September 17th

Detailed price information for Movado Group Inc (MOV-N) from The Globe and Mail including charting and trades.

12d agoThe Globe and Mail

Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present during the H.C. Wainwright & Co. 28th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026. A live webcast will be available on the Events and Presentations section of Assembly Bio’s website, and a replay will be

19d agoYahoo Finance

Zacks.com featured highlights include EuroDry, RCM, Assembly Biosciences, Delcath and National Energy Services

EuroDry, RCM Technologies, Assembly Biosciences, Delcath Systems and National Energy Services show strong price momentum after August's market gains.

21d agoYahoo Finance

Also Discussed

Investors talking about ASMB also mention

#	Name	Attention
1	Aprea Therapeutics, Inc.APRE	0%0
2	ACHL - Achilles Therapeutics plc	——
3	Ovid Therapeutics Inc.OVID	0%0
4	ADVM - Adverum Biotechnologies, Inc.	——
5	State Street My2028 Corporate Bond ETFMYCH	0%0
6	OFS Capital Corporation 4.95% Notes due 2028OFSSH	0%0
7	CytomX Therapeutics, Inc.CTMX	0%0
8	iotaSN9	0%new
9	IOTAIOTA	0.03%-0.07
10	Onfolio Holdings, Inc.ONFO	0%-0.05

Assembly Biosciences Inc.

Healthcare
Biotechnology

Assembly Biosciences Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapeutics for serious viral and liver diseases. Its current pipeline includes investigational treatments for recurrent genital herpes, hepatitis B virus, hepatitis D virus, and other infectious conditions, with programs designed to target key stages of viral replication and disease progression. The company also advances research in related areas such as cholestatic liver disease and microbiome-linked disorders through orally delivered therapeutic candidates. Assembly Biosciences Inc. works across discovery, preclinical, and clinical development, positioning itself within the infectious disease and liver disease segments of the biotechnology market. Headquartered in South San Francisco, California, the company concentrates on creating novel treatment approaches intended to address unmet medical needs in virology and liver health.

Website

Location

Two Tower Place

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about ASMB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Jul 17

The stock price of ASMB is expected to increase to 3.00+ with high confidence.
A trade idea involves buying the $ASMB 30 Call for August 21 at 2.00.
ASMB is looking strong and is expected to continue increasing in value.

Generated by AI

Sentiment

Of the messages about ASMB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% +7.14	96.47% +9.44
Bearish	—	0% 0	0% -7.14	3.53% -9.44

Bullish· Jan 30

Assembly Biosciences, Inc. ($ASMB) has broken out and is gapping up, with some investors expecting a takeover by Gilead in the near future.
Closing above $1.16 per share would put $ASMB above the price Gilead paid to invest and collaborate with the company.
A strong close above $1.00 per share could meet the stock price requirements for a listing on the Nasdaq exchange.

Bearish· Oct 18

The market makers are allegedly shaking out weak hands in $ASMB, indicating a potential stop loss raid.
The significant short interest in $ASMB, with nearly 22M shares shorted yesterday, may be contributing to the current price drop.
The company's poor track record of cash utilization and preclinical/early-stage partnership deals, such as the Gilead partnership, may be causing investors to lose confidence in $ASMB.

Generated by AI

Topics

Of the messages about ASMB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	60%	79.86%
Earnings	0%	0%	0%	0.35%
Analysts	0%	0%	40%	14.84%
Controversies	0%	0%	0%	0.71%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	4.24%

Earnings· Feb 27

Assembly Biosciences, Inc. ($ASMB) is expected to announce earnings of -$0.79 per share.
The expected earnings announcement is related to the company's financial performance.
The earnings announcement is expected to provide insight into the company's financial health.

Announcements· Aug 8

Assembly Biosciences, Inc. (ASMB) announced positive interim results from its Phase 1b clinical study of ABI-5366, showing reductions in viral shedding rate and genital lesion rate in recurrent genital herpes.
ASMB has entered into a private placement with Gilead Sciences (GILD), where Gilead will purchase 2.3 million shares of ASMB common stock and accompanying Class A warrants and Class B at a price of $19.60 per share.
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings, with the company planning to use the funds to support the development of its chronic viral disease treatments, including ABI-5366.

Technical Analysis· Oct 17

The stock has shown a strong bullish engulfing pattern on the quarterly chart, indicating a potential continuation of the rally.
The Relative Strength Index (RSI) has exited the oversold zone, indicating a shift in the trend to a more bullish direction.
The stock has formed an inverted head and shoulders pattern, which is a bullish reversal pattern, and has also shown a breakout from the 18 level, indicating a potential continuation of the uptrend.

Generated by AI

Community

Of the messages about ASMB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	33.33%	63.64%	56.73%
Newcomers	100%	66.67%	36.36%	43.27%

Regulars· Feb 12

The open short interest for Assembly Biosciences Inc ($ASMB) has decreased to a micro float of 5.8 million outstanding shares.
The company's stock price is down, and its float is considered a micro float.
A catalyst or any momentum will be necessary to send the stock price higher.

Newcomers· Jul 17

Newcomers are bullish on $ASMB, expecting it to reach 3.00+.
Many are focusing on the $ASMB 30 Call for August 21 with prices ranging from 1.80 to 2.00.
Some are tracking their transactions and transactions history with $ASMB.

Generated by AI

Assembly Biosciences

Social

Jul 17

Bullish· Jan 30

Bearish· Oct 18

Earnings· Feb 27

Announcements· Aug 8

Technical Analysis· Oct 17

Regulars· Feb 12

Newcomers· Jul 17

New Strong Buy Stocks for September 17th

Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference

Why is Assembly Biosciences stock surging today?

Assembly Bio stock gains after exercising Gilead profit option

Assembly Bio opts into 40% U.S. profit share for herpes drug

Zacks.com featured highlights include EuroDry, RCM, Assembly Biosciences, Delcath and National Energy Services

Also Discussed

Assembly Biosciences Inc.

Company Information

Location

New Strong Buy Stocks for September 17th

Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference

Why is Assembly Biosciences stock surging today?

Assembly Bio stock gains after exercising Gilead profit option

Assembly Bio opts into 40% U.S. profit share for herpes drug

Zacks.com featured highlights include EuroDry, RCM, Assembly Biosciences, Delcath and National Energy Services

Also Discussed

Social

Jul 17

Bullish· Jan 30

Bearish· Oct 18

Earnings· Feb 27

Announcements· Aug 8

Technical Analysis· Oct 17

Regulars· Feb 12

Newcomers· Jul 17